Pernix Therapeutics Holdings, Inc. (“Pernix” or the “Company”) PTX, a specialty pharmaceutical company, today announced that the Company has
initiated the integration of its Pernix and Hawthorn sales forces. The Company
has restructured the combined sales force, reducing the number of sales
representatives to approximately 125 from 187. The sales force will remain
focused on Pediatrics, Primary Care and Gastroenterology.
The Company today also announced that David Becker will resign his position as
Chief Financial Officer, due to personal reasons, effective March 31, 2013.
The Company has started a search to identify a new Chief Financial Officer.
Upon naming a successor, Mr. Becker will serve the Company as a consultant in
several areas, including manufacturing, over-the-counter products, and
business development.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in